TP53 and neoplasm: Although antiangiogenic therapy targets genetically stable endothelial cells in the tumour vasculature, tumour cells with mutated p53 are less susceptible to apoptosis under hypoxic conditions, resulting in reducing their reliance on vascular supply, and hence their responsiveness to antiangiogenic therapy (Yu et al, 2002).